Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Budicort is a brand name for budesonide, a potent synthetic corticosteroid with strong glucocorticoid activity and negligible mineralocorticoid effect. It is primarily used as an anti-inflammatory agent for the maintenance treatment of asthma and the prevention of asthma exacerbations. The drug is typically administered via inhalation using a Turbohaler device, which delivers the medication directly to the airways. Budesonide works by binding to and activating the glucocorticoid receptor, which subsequently modulates gene transcription to inhibit the production of inflammatory mediators such as cytokines, leukotrienes, and prostaglandins. This action reduces airway inflammation and bronchial hyperresponsiveness, helping to control symptoms and prevent attacks in patients with chronic respiratory conditions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Budicort.